Cargando…
[(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) Angiogenesis PET/MR in a Porcine Model of Chronic Myocardial Infarction
Angiogenesis is crucial in tissue repair and prevents scar tissue formation following an ischemic event such as myocardial infarction. The ischemia induces formation of new capillaries, which have high expression of integrin α(v)β(3). [(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) ([(68)Ga]Ga-RGD) is a promising...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535023/ https://www.ncbi.nlm.nih.gov/pubmed/34679505 http://dx.doi.org/10.3390/diagnostics11101807 |
Sumario: | Angiogenesis is crucial in tissue repair and prevents scar tissue formation following an ischemic event such as myocardial infarction. The ischemia induces formation of new capillaries, which have high expression of integrin α(v)β(3). [(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) ([(68)Ga]Ga-RGD) is a promising PET-radiotracer reflecting angiogenesis by binding to integrin α(v)β(3). A Göttingen mini-pig underwent transient catheter-induced left anterior descending artery (LAD) occlusion for 120 min, and after 8 weeks was imaged on a Siemens mMR 3T PET/MR system. A large antero-septal infarction was evident by late gadolinium enhancement (LGE) on the short axis and 2–4 chamber views. The infarcted area corresponded to the area with high [(68)Ga]Ga-RGD uptake on the fused PET/MR images, with no uptake in the healthy myocardium. To support the hypothesis that [(68)Ga]Ga-RGD uptake reflects angiogenesis, biopsies were sampled from the infarct border and healthy myocardium. Expression of α(v)β(3) was evaluated using immunohistochemistry. The staining showed higher α(v)β(3) expression in the capillaries of the infarct border compared to those in the healthy myocardium. These initial data confirm in vivo detection of angiogenesis using [(68)Ga]Ga-RGD PET in a translational model, which overall support the method applicability when evaluating novel cardio-protective therapies. |
---|